Tyler Kenneth L
Department of Neurology, University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, Denver, Colorado 80262, USA.
Herpes. 2004 Jun;11 Suppl 2:57A-64A.
Herpes simplex encephalitis (HSE) is a life-threatening consequence of herpes simplex virus (HSV) infection of the central nervous system (CNS). Although HSE is rare, mortality rates reach 70% in the absence of therapy and only a minority of individuals return to normal function. Antiviral therapy is most effective when started early, necessitating prompt diagnosis. The International Herpes Management Forum (IHMF) has issued guidelines to aid the diagnosis and treatment of HSE. Polymerase chain reaction (PCR) of the cerebrospinal fluid (CSF) is the diagnostic method of choice for HSE, but negative results need to be interpreted in the context of the patient's clinical presentation and the timing of the CSF sampling. CSF virus culture is of little value in all but patients under the age of 6 months. CSF (intrathecal) antibody measurements are not recommended for acute diagnostic purposes. However, demonstration of an intrathecal HSV antibody response may be helpful in retrospective diagnosis or in cases in which CSF is sampled only late after onset of infection and PCR is negative. Serum HSV antibody measurements are not of utility in the diagnosis of HSV encephalitis in adults. In children and young adults, HSV serology may help define whether HSE is part of a primary or a reactivated HSV infection, although the clinical features, therapy, and prognosis of these two forms of HSV encephalitis are similar. The IHMF recommends that all patients with HSE receive intravenous aciclovir 10 mg/kg every 8 h for 14-21 days. Owing to the life-threatening nature of the disease, if there is a delay in diagnostic test results therapy should not be withheld until they become available. After completion of therapy, PCR of the CSF can confirm the elimination of replicating virus, aiding further management of the patient. Clinical trials of other antiviral agents (i.e. adjunctive oral valaciclovir after intravenous aciclovir) for the treatment of HSE are underway. Herpes infection of the CNS, especially with HSV-2, can also cause both monophasic and recurrent aseptic meningitis, as well as myelitis or radiculitis. Limited evidence suggests that aciclovir may be effective in its treatment. Recurrent aseptic meningitis is predominantly caused by HSV-2 infection, and is characterized by self-limited episodes of fever, meningismus and severe headache. Many cases are indistinguishable from cases previously classified as "Mollaret's meningitis", a term that should now be reserved for idiopathic cases of recurrent aseptic meningitis.
单纯疱疹病毒性脑炎(HSE)是单纯疱疹病毒(HSV)感染中枢神经系统(CNS)导致的一种危及生命的后果。尽管HSE较为罕见,但在未接受治疗的情况下死亡率可达70%,只有少数患者能恢复正常功能。抗病毒治疗尽早开始最为有效,因此需要迅速诊断。国际疱疹管理论坛(IHMF)已发布指南以协助HSE的诊断和治疗。脑脊液(CSF)的聚合酶链反应(PCR)是HSE的首选诊断方法,但阴性结果需要结合患者的临床表现和CSF采样时间来解读。CSF病毒培养除了对6个月以下的患者外几乎没有价值。不推荐将CSF(鞘内)抗体检测用于急性诊断目的。然而,证明鞘内HSV抗体反应可能有助于回顾性诊断,或有助于诊断感染发作后很晚才采集CSF且PCR结果为阴性的病例。血清HSV抗体检测对成人HSV脑炎的诊断没有帮助。在儿童和年轻成人中,HSV血清学检测可能有助于确定HSE是原发性还是复发性HSV感染的一部分,尽管这两种形式的HSV脑炎的临床特征、治疗方法和预后相似。IHMF建议所有HSE患者接受静脉注射阿昔洛韦,剂量为每8小时10mg/kg,持续14 - 21天。由于该疾病危及生命,如果诊断测试结果延迟,不应在结果出来之前推迟治疗。治疗结束后,CSF的PCR检测可以确认复制病毒已被清除,有助于对患者进行进一步管理。其他抗病毒药物(如静脉注射阿昔洛韦后辅助口服伐昔洛韦)治疗HSE的临床试验正在进行中。CNS的疱疹感染,尤其是HSV - 2感染,也可引起单相性和复发性无菌性脑膜炎,以及脊髓炎或神经根炎。有限的证据表明阿昔洛韦可能对其治疗有效。复发性无菌性脑膜炎主要由HSV - 2感染引起,其特征为发热、颈项强直和严重头痛的自限性发作。许多病例与以前归类为“莫拉雷脑膜炎”的病例难以区分,现在“莫拉雷脑膜炎”这个术语应仅用于复发性无菌性脑膜炎的特发性病例。